Other research analysts have also recently issued reports about the company. BidaskClub raised Cutera from a buy rating to a strong-buy rating in a research note on Tuesday, November 5th. Sidoti lowered Cutera from a buy rating to a neutral rating in a research report on Thursday, August 22nd. Stephens raised their price target on Cutera from $35.00 to $45.00 and gave the stock an overweight rating in a research report on Friday, November 8th. Maxim Group reiterated a hold rating on shares of Cutera in a report on Friday, August 9th. Finally, Zacks Investment Research lowered Cutera from a hold rating to a sell rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $40.00.
CUTR traded up $0.38 during mid-day trading on Tuesday, hitting $37.47. The stock had a trading volume of 152,483 shares, compared to its average volume of 171,898. The stock’s fifty day simple moving average is $34.30 and its 200-day simple moving average is $27.26. The firm has a market capitalization of $533.31 million, a price-to-earnings ratio of -16.80 and a beta of 0.96. Cutera has a 1-year low of $12.32 and a 1-year high of $39.15. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.66 and a quick ratio of 1.05.
Cutera (NASDAQ:CUTR) last released its quarterly earnings data on Thursday, November 7th. The medical device company reported $0.15 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.23. Cutera had a negative net margin of 20.84% and a negative return on equity of 84.67%. The business had revenue of $46.12 million during the quarter, compared to analysts’ expectations of $41.66 million. During the same quarter in the prior year, the company earned $0.11 EPS. The firm’s quarterly revenue was up 13.7% on a year-over-year basis. As a group, research analysts expect that Cutera will post -0.71 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the company. California State Teachers Retirement System raised its holdings in shares of Cutera by 1.3% during the third quarter. California State Teachers Retirement System now owns 21,548 shares of the medical device company’s stock worth $630,000 after acquiring an additional 269 shares during the period. State Street Corp increased its holdings in Cutera by 25.8% during the 3rd quarter. State Street Corp now owns 465,757 shares of the medical device company’s stock worth $13,614,000 after purchasing an additional 95,597 shares in the last quarter. Eqis Capital Management Inc. bought a new position in Cutera during the 3rd quarter worth about $278,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Cutera in the 3rd quarter valued at about $287,000. Finally, Mackay Shields LLC acquired a new stake in shares of Cutera in the 3rd quarter valued at about $1,566,000. 91.46% of the stock is owned by institutional investors.
Cutera Company Profile
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Featured Article: How are institutional investors different from individual investors?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.